PharmacoEconomics & Outcomes News 784, p31 - 12 Aug 2017 Widespread statin use under NICE 2014 guidelines Statin treatment would be required by 11.8 million adults in England under the UK NICE 2014 guidelines for cardiovascular risk and lipid modification, according to an article in the British Journal of General Practice. The 2014 update of the NICE guidelines reduced the treatment threshold for statin therapy from the previous 10-year cardiovascular risk level of 20% or over, to 10% or over, for all adults without a previous history of cardiovascular disease. In addition, the guideline update endorsed the QRISK2 algorithm to estimate cardiovascular risk. A cross-sectional study was conducted to investigate risk factor levels required to exceed the risk threshold for statin therapy, and to estimate statin usage, based on the 2014 guidelines. Using data from the Health Survey for England, the 10-year cardiovascular risk for adults aged 30–84 years was estimated by inputting varying combinations of risk factors into the QRISK2 algorithm. Even with optimal risk factor levels, the authors found that the 10-year cardiovascular risk threshold would be exceeded by males between the ages of 60 and 70 years, and by females between the ages of 65 and 75 years, regardless of ethnicity. Under the 2014 NICE guidelines, 11.8 million adults aged 30–84 years in England would require statin therapy, which would represent 37% of this demographic. Almost two-thirds of the 9.8 million people without cardiovascular disease who would require statins under the guidelines were eligible for, but not receiving, statin treatment. Discussing the implications of the findings for practice, the authors highlighted that "even if providing statin therapy to a large part of the population is deemed to be cost-effective, it will still require resources to screen, treat, and monitor the patients who are put on treatment". Ueda P, et al. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis. British Journal of General Practice : 31 Jul 2017. Available from: URL: https://doi.org/10.3399/bjgp17X692141 803263658 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera